BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31482226)

  • 1. Population pharmacokinetics of siltuximab: impact of disease state.
    Nikanjam M; Yang J; Capparelli EV
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose selection of siltuximab for multicentric Castleman's disease.
    Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
    Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
    van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
    J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
    Xu C; Han C; Marini J; Ford J; Marciniak S; Lopez M; Frederick B; de Vries D; Bandekar R; Davis HM; Zhou H; Puchalski TA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):328-34. PubMed ID: 27128840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
    Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
    Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.
    Nikanjam M; Stewart CF; Takimoto CH; Synold TW; Beaty O; Fouladi M; Capparelli EV
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):495-503. PubMed ID: 25557868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
    Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
    Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report.
    Marchetti M; Feyles E; Zinzani P
    Eur J Haematol; 2020 Oct; 105(4):505-507. PubMed ID: 32564425
    [No Abstract]   [Full Text] [Related]  

  • 19. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N
    Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.